Posts Tagged ‘psychiatry’

DSM 5 in Distress—Seven Questions For Professor Patrick McGorry

Friday, August 19th, 2011

Psychology Today – August 18, 2011

by Allen Frances, M.D.

Psychiatry cannot promise more than it can deliver.

Whenever contradicted, Professor McGorry attacks the motives of the messenger rather than providing any reasoned rebuttal to the message.

The great news is that Professor McGorry has recently renounced the relevance of psychosis risk syndrome in the current practice of clinical psychiatry. He has done so in two separate and dramatic ways: 1) by withdrawing his support for the inclusion of psychosis risk in DSM 5; and 2) by promising not to include it as a target in Australia’s massive new experiment in early intervention. Psychosis risk syndrome is an extremely promising topic for ongoing research, but it is not nearly ready for current clinical application and if introduced prematurely could cause disastrous unintended consequences.

Professor McGorry’s sharp about face on both fronts could well be a wonderful double game changer. He is by far the most powerful psychiatrist in the world and an absolutely brilliant politician. Leveraging his unique stature as 2010 ‘Australian Of The Year,’ McGorry has succeeded in gaining the support of all the major Australian parties in the funding of a large and much needed investment in the country’s mental health. His new caution on psychosis risk will influence others to be less venturesome in prematurely promoting this potentially dangerous diagnostic proposal.

But a dark cloud surrounds the silver lining of having one psychiatrist in a position of almost unopposed influence. Professor McGorry has developed the messianic blind spot that is so common in visionary prophets. His zeal has made him an unreliable evaluator of scientific evidence, allowing him to defend absolutely indefensible positions with the convincing, but inaccurate, force of a true believer. A review of Professor McGorry’s public statements shows his willingness to ignore any evidence contrary to his belief, to change stated views back and forth when he regards this to be necessary or convenient, and to unfairly attack those who point out the fallacies and inconsistencies in his comments. His are the skills of a prophet and rainmaker, not those of a policy maker or a program developer or a sober reviewer of scientific evidence.

The most telling example of the McGorry blind spot was his ready dismissal of a recent Cochrane review that has discredited his extravagant claims for early intervention. This independent, systematic, comprehensive, and rigorous review of the scientific literature concluded there was insufficient scientific evidence to support McGorry’s grand assertions that early intervention programs promote enduring change and can reduce the lifelong burden and cost of illness. Early intervention does seem to be helpful temporarily while it is being provided, but does not seem to have any lasting impact on the course or cost of illness once it is stopped.

So, the Cochrane group lines up on one side and McGorry lines up on the other. Who to believe? The Cochrane group is widely credited for its impartiality and esteemed for its expertise in all aspects of scientific review. Its reports are considered a gold standard, exerting great influence on state of the art, evidence based medical practice throughout the world, particularly in Great Britain. One might expect that Cochrane’s stainless reputation would daunt a person even of Professor McGorry’s extraordinary power and blind conviction. But no. When the Cochrane report disappoints his expectations and fails to nourish his prejudices, McGorry feels no hesitation in attacking it, criticizing its methodology, and dismissing its discouraging conclusions. His rebuttal of the Cochrane group consists only of his personal endorsement of early intervention accompanied by the blithe (but empty) claim that it has strong supporting evidence. As far as McGorry is concerned, Cochrane be damned. Such idiosyncratic evaluation of scientific evidence cannot be trusted as a sensible foundation for mental health policy.

This is part of a pattern, not one isolated and exceptional instance of blind spot. Whenever contradicted, Professor McGorry attacks the motives of the messenger rather than providing any reasoned rebuttal to the message. His skill in the parry/thrust of the political sound bite is matched by an unwillingness to subject his views to anything resembling fact based discussion. When I expressed doubts about Dr McGorry’s excessive claims for his prevention model, he twisted my concerns to suggest that somehow I was defending the traditional US model of care against his innovative Australian model. This silly and totally incorrect attempt at diversion had not the slightest relevance to my two real motivations. Primary is the fear that by ambitiously overselling itself, psychiatry does a disservice to its patients and harm to its core mission and credibility. I believe strongly that scarce mental health resources must be judiciously spent to provide care for those who clearly need them- with continuity that starts with the first episode and lasts until they have either become well enough to do without or are dead. I therefore object to squandering vast resources upfront on those who may not need them using what are premature and still unproven methods. My secondary motivation (now somewhat assuaged by McGorry’s recanting, if he sticks to it) is the fear that the recognition of psychosis risk syndrome as an official diagnosis in DSM 5 and/or as a target in EPPIC programs will result in unnecessary stigma for the misidentified and dangerous off label overprescription of antipsychotic drugs.

McGorry has also tried to stifle his Australian critics- consistently evading their well reasoned and empirically supported arguments with the false innuendo that their motivation is simply to protect turf. His distraction technique employs catchy phrases (“Merchants of doubt do no favours for people with mental illnesses”) and dismissive insults (critics are a ‘cadre’). This so called ‘cadre’ of ‘merchants of doubt’ happen to be highly respected colleagues who are doing precisely what needs to be done- challenging McGorry in an open discussion of his excessive claims and of his idiosyncratic take on the literature. They are trying to protect Australia from blindly making a risky public health bet promoted by a stubborn ‘true believer’ who refuses to engage in meaningful dialog and cannot be unconvinced even by clearest evidence contradicting his personal belief system. It is crucial that scientists and policy makers always be honest and skeptical ‘merchants of doubt’ -not joiners in a parade of the credulous marching blindly off a cliff. McGorry needs to meet opposition with facts and rational debate, not innuendo and insult.

This brings me to my immediate purpose here. Let’s all get off the personal and focus instead on the issues. Below are seven questions that beg for Dr McGorry’s immediate public response. No evasion or questioning of my motivation is called for- just straight answers to simple questions. It will be useful for Professor McGorry to respond for the record now, before Australia’s makes final the terms of its much needed and awaited investment in mental health.

Question 1) Please spell out on what scientific basis you have dismissed the findings of the Cochrane report and indicate why Australia should base policy decisions on your personal interpretation of these data rather than on Cochrane’s more objective and systematic approach?

Question 2) What will be your role in establishing the goals and in directing the implementation of Australia’s early intervention programs and what protections are in place to ensure that opposing voices and interpretations get a fair hearing? Who else will be involved in the governance of these programs and how will they be selected?’

Question 3) Can you now state with certainty that the newly
funded early psychosis intervention programs will be restricted exclusively to those who are already diagnosed with definite psychosis and will definitely not include individuals deemed to be only at some increased risk for future psychosis?

Question 4) Do you now agree that it is inappropriate to prescribe antipsychotic medication for psychosis risk except under the close supervision of an approved research protocol?

Question 5) What protections will be in place to avoid the premature and incorrect differential diagnosis of psychosis? The distinction between prepsychotic and psychotic is much clearer on paper than in practice and psychotic symptoms in teenagers are often transient, caused by substance abuse or mood disorder. Will strict diagnostic requirements, careful differential diagnosis, and quality control guard against incorrect, premature, and stigmatizing diagnoses and also against unnecessary and potentially harmful treatments?

Question 6) Why not roll out the EPPIC programs in gradual steps? This would ensure that the model translates well from the research environment to day to day practice and would provide an opportunity to demonstrate its efficacy and cost effectiveness before disproportionate investments are made in it.

Question 7) How do you justify the funding shortfalls for other necessary continuity of care programs that will likely be caused by the front ending of expenditures for EPPIC (especially given lack of convincing evidence that EPPIC confers enduring benefits or any reduction in future need for, or cost of, services)? Is it worth staking such a large proportion of the mental health budget on such an uncertain roll of the dice?

His track record makes clear that Professor McGorry can not be relied upon as a neutral reviewer of scientific evidence or a neutral advisor on the question of which mental health investments will bring to Australians the highest and safest returns. His countrymen should be very grateful to Professor McGorry for having obtained desperately needed funding for mental health, but should also be cautious in following his lead in determining how to best to allocate it. The mental health situation in Australia is without historic precedent. Never before has the future direction of an entire country’s mental health program depended almost solely on the unopposed opinions and actions of one charismatic psychiatrist and his band of loyal followers. His inordinate power places a huge responsibility on Professor McGorry to exercise responsible and responsive leadership. Direct answers to the questions raised above are needed to ensure that public policy will follow the scientific evidence and not be unduly influenced by the blinkered zeal of one man, however well meaning and highly respected he may be.

http://www.psychologytoday.com/blog/dsm5-in-distress/201108/seven-questions-professor-patrick-mcgorry

 

« Return to news items


Share

ADHD drugs linked to heart disease and death

Thursday, August 4th, 2011

NaturalNews – August 2, 2011

by Ethan A. Huff

Click image to watch 1 minute video: ADHD—Labeling Normal Kids 'Mentally Ill'

A major study recently published in the journal Pediatrics — and republished by countless other medical and mass media sources — made the bold claim that stimulant drugs like those used to treat attention deficit hyperactivity disorder (ADHD) in children are not linked to cardiovascular events and death. But a recent analysis by Dr. Robert Tozzi writing for FOX News explains that the study was flawed, and that the drugs will cause cardiovascular events or death, especially in individuals with certain conditions.

Like most studies that allege the safety of pharmaceutical drugs, the Pediatrics study was at least partially, if not completely, funded by the drug industry. It was also deliberately constructed in such a way as to artificially minimize the risks associated with stimulant drugs. As a result, its findings ended up mirroring claims long made by the drug industry that stimulant drugs are safe, and that children do not need to be tested for certain conditions prior to being prescribed them.

The study included two groups of children, one taking stimulant drugs, and the other not taking stimulant drugs. The idea was to simply compare the number of heart events between the two groups, and determine whether or not stimulant drugs are associated with an increased risk of heart events and sudden death.

Well, according to Dr. Tozzi, few, if any, of the high-risk children with conditions that would react negatively in the presence of stimulants were placed in the stimulant group. Most parents of children with such conditions, as well as their doctors, would not normally opt for giving stimulants to their high-risk children, and thus the vast majority of these children were placed in the non-stimulant group.

This inherent and obvious flaw completely debunks the credibility of the study. After all, the whole point of it was supposedly to identify whether or not children need to be pre-screened for certain conditions before being prescribed stimulant drugs. With this in mind, it makes sense to actually identify how children with existing conditions respond to stimulant drugs, otherwise the data is meaningless.

It is difficult to say which is worse — testing dangerous drugs on high-risk children, or not testing dangerous drugs on high-risk children and simply declaring that they are  safe (which is what the drug industry basically did in a recent study). One thing is for sure, though. The propositions made in the study that stimulant drugs are safe and do not raise the risk of heart disease and sudden death are patently false. And many children will likely suffer and die as a result of these lies.

To read all international drug regulatory warnings and studies on Ritalin, Adderall, Concerta and other ADHD drugs visit CCHR’s Psychiatric Drug Side Effects Search Engine”

http://www.cchrint.org/psychdrugdangers/drug_warnings.php

http://www.naturalnews.com/033204_ADHD_drugs_death.html

« Return to news items


Share

DSM 5 Will Further Inflate The ADD Bubble

Tuesday, August 2nd, 2011

Psychology Today
by Allen Frances, Former Chairman, DSM Task Force

Video: ADHD Labeling Normal Kids "Mentally Ill"

The Child Work Group Fails Again To Learn From Its Experience

Martin Whiteley is an MP who represents Perth in the Australian parliament. He has been actively involved in mental health issues and succeeded in a crusade to curb what had been Perth’s alarming overdiagnosis and overmedication of  Attention Deficit Disorder Disorder (ADD). Mr Whiteley has become expert in the intricacies of ADD and is alarmed that the changes suggested for DSM 5 will greatly exacerbate the ADD fad he worked so hard to tame. Read Mr Whiteley’s careful item by item review and you will be alarmed too:

http://speedupsitstill.com/dsm-5-proposal-adhd-%e2%80%93-making-l…

We are already in the midst of a false epidemic of ADD. Rates in kids that were 3-5% when DSM IV was published in 1994 have now jumped to 10%. In part this came from changes in DSM IV, but most of the inflation was caused by a marketing blitz to practitioners that accompanied new on-patent drugs amplified by new regulations that also allowed direct to consumer advertising to parents and teachers. In a sensible world, DSM 5 would now offer much tighter criteria for ADD and much clearer advice on the steps needed in its differential diagnosis. This would push back ,however feebly, against the skilled and well financed drug company sell. DSM 5 should work hard to improve its text, not play carelessly with the ADD criteria in a way that may unleash a whole set of dreadful unintended consequences- unneeded medication, stigma, lowered expectations, misallocation of resources, and contribution to the illegal secondary market peddling stimulants for recreation or performance enhancement.

The DSM 5 child and adolescent work group has perversely gone just the other way. It proposes to make an already far too easy diagnosis much looser.

How puzzling and troubling. Child mental health has already promoted no fewer than three false epidemics in just 15 years- ADD, childhood bipolar, and autism. Any reasonable group would now be learning from this past experience. For the future, it would be chastened, cautious, and eager to correct the damage it has done- rather than embarking on any reckless new adventures. A prudent DSM 5 would tighten its criteria for ADD and put in a black box warning against the blatant current off-the-DSM-label diagnosis of childhood bipolar. DSM 5 instead does everything wrong it possibly could with ADD and then remarkably takes the mischievous further step of adding yet another new candidate for diagnostic fad (Disruptive Mood Dysregulation Disorder) likely that will increase the already scandalous overprescription of dangerous antipsychotic medication to children. Go figure.

In many circles, the accepted wisdom is that DSM 5 workers are making such unaccountably bad decisions because they want to promote drug sales to kids. To support this accusation, cynics raise the Biederman affair and also APA’s previous excessive financial support from Pharma.

This is one time when the cynics are dead wrong. The DSM 5 work group is making simply disastrous decisions for the purist of reasons. These are not people with close industry ties and their conflict of interest is intellectual, not financial. Experts in child psychiatry are dangerously naïve about the likely misuses of their well meaning suggestions. They are blind, not corrupt.

What is needed is outside supervision to curb child psychiatry’s seemingly endless taste for diagnostic excess. And APA should also realize the grave harm done to its credibility by the appearance that DSM 5 is far too Pharma friendly even if this has not been the real motivation behind the bad DSM 5 proposals.

To make matters worse, the DSM 5 field trial will be completely worthless- providing no information at all about the magnitude of the rate increase in ADD that will occur once DSM 5 opens the floodgates even wider. We did careful field trials before DSM IV to compare the impact on rates of the different possible definitions and predicted a 15% increase for the one finally chosen. Instead, the rates more than doubled- courtesy of pressure from the drug companies. For obscure reasons, DSM 5 is conducting extraordinarily expensive field trials that (again perversely) avoid the only question that really counts- just how high will the rates skyrocket under the even easier to meet new DSM 5 definition.

DSM 5 will be flying completely blind into dangerous territory, unimpeded by adult supervision. The leaders of child psychiatry (who already have the unfortunate track record of producing fads) will now be given a free pass to further feed their blossoming ADD fad. Will they never learn from past mistakes?

http://www.psychologytoday.com/blog/dsm5-in-distress/201108/dsm-5-will-further-inflate-the-add-bubble

« Return to news items


Share

America conned: Psycho pharma drug pushing empire under fire

Tuesday, July 26th, 2011

NaturalNews – July 26, 2011

by Monica G. Young

"psychopharma is looking like an idea whose time has passed."

Is America truly stricken with widespread mental illness? Do tens of millions need mind-altering drugs? A recent flurry of media articles lead readers to a realization that Big Pharma and the “mental health” industry have deceived Americans on a grand scale.

The “New York Review of Books” two-part article by Dr. Marcia Angell, Senior Lecturer at Harvard Medical School and former Editor in Chief of The New England Journal of Medicine, summarizes it extremely well. She analyzes three books by authors Irving Kirsch, Robert Whitaker, and Daniel Carlat. Each deconstructs the apparent mental illness epidemic and theory that mental disorders stem from brain chemical  imbalances which can be corrected by drugs.

Dr. Angell’s review has sparked a host of other journalists to applaud her and fuel the fire. An article in Forbes even concludes, “psychopharma is looking like an idea whose time has passed.”

As an overview:

Ten percent of Americans over age six take antidepressants. Antipsychotic drugs, once reserved for schizophrenics, have become the top-selling class of drugs in the US, with over $14 billion in sales in 2009. ADHD, bipolar and autism diagnoses have exploded in the past two decades with at least 5 million US kids now on psychiatric drugs.  Ten percent of boys take drugs for ADHD. Half a million kids take antipsychotics, including preschoolers.

The chemical imbalance theory rose to fame when Prozac hit the market in 1987, accompanied by massive hype that it corrected a chemical deficiency in the brain. In the years that followed, the number of people prescribed drugs for mental illness skyrocketed. Today, “treatment” for mental disorders is synonymous with psychoactive (mind-altering) drugs.

Tracing the origin of this theory shows it wasn’t that chemical imbalances were discovered in the mentally ill and then drugs were devised to correct the imbalance. Instead, drugs created for other purposes were incidentally found to also affect brain chemicals and blunt mental symptoms. Drug companies, hungry for new markets, and   psychiatry, eager to build stature in the medical arena, leapt on this. They conducted a vast campaign to popularize chemical imbalances as the cause of mental disturbance and push drugs as the answer.

As Dr. Angell writes, “instead of developing a drug to treat an abnormality, an abnormality was postulated to fit a drug.” “Or similarly,” she says, “one could argue that fevers are caused by too little aspirin.”

Many scientific studies disprove the chemical imbalance theory. After fifteen years of research, Irving Kirsch – psychologist and author of “The Emperor’s New Drugs” – concludes, “It now seems beyond question that the traditional account of depression as a chemical imbalance in the brain is simply wrong.” Research studies show psychoactive medications actually disrupt brain chemistry and causes the brain to function abnormally. This year prominent neuroscientist, Dr. Nancy Andreason, announced proof that antipsychotics shrink the brain.

Studies also demonstrate that long-term recovery rates are higher for nonmedicated patients. For instance, the World Health Organization conducted an investigation in fifteen cities around the world and out of 740 depressed individuals studied, those that weren’t on psychiatric drugs had the best long term outcomes.

In the pre-medication era, it was known that with time, people usually recovered from depression. If kids had tantrums, were unruly or shy, they were apt to outgrow it. Today, individuals branded with disorders are likely to receive long-lasting diagnoses, endless prescriptions and the poorer ones tend to remain on disability for life.

Big Pharma manipulation

Dr. Marcia Angell says the author of each of the three books agrees on “the disturbing extent to which the companies that sell psychoactive drugs – through various forms of marketing, both legal and illegal, and what many people would describe as bribery – have come to determine what constitutes a mental illness and how the disorders should be diagnosed and treated.”

According to IMS Health, an information and consulting company, pharmaceutical companies spent $6.1 billion in 2010 in marketing to US doctors. Another $4 billion was spent on direct-to-patient advertising.

Drug trials, used to bring a drug to market, are funded by drug companies, heavily biased and misleading. Companies may sponsor as many trials as they like until they have just two positive ones to submit to the FDA. Great care is taken to hide negative trials. The highly positive results of placebo trials are downplayed: a high percentage of patients recover on a fake drug (like a sugar pill) – proving that the more a person believes he will benefit from a treatment, the more likely he will experience a benefit.

In regards the Diagnostic and Statistical Manual – the psychiatric bible of mental disorders, used in prescribing drugs – Dr. Angell points out “in all of its editions, it has simply reflected the opinions of its writers.” The majority of the psychiatrists involved in creating the current edition had financial ties to drug companies.

Author Daniel Carlat points out that “psychiatrists consistently lead the pack of specialties when it comes to taking money from drug companies.”

Crime against humanity

And where has the “mental health” industry and “drug therapy” brought our nation?

As Americans line up at their local pharmacy, documented side effects are legion: weight gain, deadened emotions, diabetes, heart problems, liver damage, stunted growth in kids, shortened life spans and on and on. Those prescribed one psychoactive drug are commonly prescribed another to address side-effects, with many on daily cocktails of meds.

An estimated 2.2 million Americans are hospitalized each year for adverse drug reactions. Over 100,000 die from them.

Instead of decreasing, the number of adults on disability pay for mental illness has soared 250% since 1987 and for kids it’s a 35X increase.

The greatest  crime to humanity is the mass drugging of children. Yet it’s perpetrated within schools, doctors offices, foster homes and juvenile facilities daily.

There is good news. In the past few years, drug companies have faced a rise of multi-billion dollar class action suits. The key popularizer of childhood bipolar and antipsychotics for kids, Dr. Joseph Biederman, was publicly sanctioned by Harvard Medical School for failing to report $1.6 million he pocketed from drug companies. Some drugmakers are steering away from pursuing new psychoactive drugs.

Nazi chief propagandist Joseph Goebbels once said, “If you tell a lie big enough and keep repeating it, people will eventually come to believe it.”

This chemical-imbalance/drug therapy lie has been told big enough and repeated enough, that much of America believes it. Isn’t it time we all put a stop to it?

« Return to news items


Share

Battling over happy pills

Tuesday, July 26th, 2011

The Boston Globe – July 26, 2011

by Alex Beam

A scholarly tug of war over treating mental disorders boils down to one question: Do antidepressants work?

In this corner: Dr. Marcia Angell, former editor in chief of the New England Journal of Medicine, senior lecturer in social medicine at Harvard Medical School, and frequent critic of the pharmaceutical industry. In the opposite corner: Dr. Peter Kramer, Brown University psychiatry professor and author of the mega-selling “Listening to Prozac,’’ a book that helped convince thousands of Americans to live better, chemically.

At issue: a two-part article by Angell, published in The New York Review of Books, that assails psychiatrists and their pharmaceutical helpmeets, mainly antidepressants, on several fronts.

Item: Angell, quoting, among others, Tufts University psychiatrist Dr. Daniel Carlat, attacks the widely held belief that depression and other mental disorders result from chemical imbalances in the brain.

Item: Citing the research of British psychologist Irving Kirsch, Angell writes that some of the most widely used antidepressants, including Prozac, Paxil, Zoloft, Celexa, and Effexor, performed only marginally better than placebos in Food and Drug Administration tests, a “clinically meaningless’’ result.

Item: Angell uses a book by journalist Robert Whitaker to suggest that newly minted antipsychotic drugs may be causing “an epidemic of brain dysfunction.’’

A few days after Angell’s essay appeared, Kramer published a lengthy essay, “In Defense of Antidepressants’’ in The New York Times. His key point: “Antidepressants work – ordinarily well, on a par with other medications doctors prescribe.’’ Kramer attacked Kirsch’s analysis of FDA drug trials, allowing that they can be “quick’’ and “sloppy,’’ and adding that the kinds of people who present themselves for drug research studies “are likely to be an odd bunch.’’

More convincingly, Kramer cited drug companies’ “maintenance studies,’’ in which patients successfully taking antidepressants switched to dummy pills. “If the drugs are acting as placebos,’’ Kramer wrote, “switching should do nothing.’’ But the drugs significantly reduced the odds of relapse. “These results, rarely referenced in the antidepressant-as-placebo literature, hardly suggest that the usefulness of the drugs is all in patients’ heads,’’ Kramer concluded.

What prompted Kramer to defend antidepressants? “I had never really come out and said that antidepressants work in ordinary ways for ordinary diseases,’’ he said. “Doctors work with these tools all the time. It’s true that these medications are imperfect, and we would all like them to be better, but we’ve all seen them work. You would have to start from a really suspicious stance to think that the whole enterprise is corrupt.’’

In an interview, Angell replied: “In his article, Kramer says it’s well established that antidepressants work for chronic and recurrent mild depression, but where is the evidence for that? That screams out for a reference. Should we believe it just because he says that?

“You can’t base judgments on anecdotes from clinical experience, because that can be very misleading,’’ Angell said. “I have faith in the evidence – in rigorous, randomized, double blind controlled clinical trials, and that’s the only way we can get at the facts. Medical history is filled with storytelling, and it is often wrong.’’

Whose side am I on? I’m biased. If there were a religion that combined the non-loony elements of Christian Science, Scientology, and Episcopalianism – a tall order, I know – I would sign right up. Psychoactive drugs frighten me. I embrace my dysphoria, although I am sensitive enough to realize that this isn’t a life strategy that works for everyone.

Also, I read Angell’s brilliant, anti-lawyer, anti-journalist book-diatribe, “Science on Trial: The Clash of Medical Evidence and the Law in the Breast Implant Case,’’ and loved it. I read Kramer’s “Listening to Prozac’’ and had trouble finding the handle.

So I appealed to Dr. Steven Hyman, former director of the National Institute of Mental Health, now a visiting scholar at the Broad Institute, for a second opinion. Angell cites some of Hyman’s work – incorrectly, he says – in her NYRB article, so I figured he would have read both her essay, and Kramer’s.

He had. Hyman didn’t have much to say about Kramer’s Times essay, other than to remark that it seemed a little hurried. He had read Angell’s article closely, and was quite familiar with Kirsch’s “Prozac as placebo’’ theories, and with Angell’s low opinion of pharmaceutical companies. “I agree with her that the marketing practices of the big pharmaceutical companies have been awful,’’ Hyman said. “But it’s a leap to say that mental illness is a pharmaceutical company invention.’’ http://www.boston.com/lifestyle/articles/2011/07/26/do_antidepressants_work/

Note from CCHR to Dr. Steven Hyman:  You’re actually correct in stating “it’s a leap to say that mental illness” [as it has been falsely pawned off on the public as a biological/medical condition] is a “pharmaceutical company invention.”  You’re right. It’s not.   Drug companies can’t vote mental disorders into existence, categorize behaviors or emotions as “disease” and then without a shred of medical/scientific evidence to support them as such – repackage these behaviors as “illness” and pawn them off on as unsuspecting public as disease.  Only psychiatry can do that.  Pharma simply funds psychiatry’s mass marketing campaigns.   For more information click here: http://www.cchrint.org/psychiatric-disorders/

 

« Return to news items


Share

Interview with “Psychiatryland” Author, Phillip Sinaikin, MD

Monday, July 25th, 2011

Scoop News – July 25, 20011

By Martha Rosenberg

"Psychiatry mimics science but is not a real science. The symptoms it treats are subjective and have not been demonstrated and cannot be demonstrated at the cellular level."

Phillip Sinaikin, MD, is a Florida psychiatrist who has been in practice for 25 years. His new book focuses on excesses and industry influence in the field of psychiatry.

Rosenberg: Your new book, Psychiatryland, traces how deception, conflicts of interest, medical enabling and direct-to-consumer advertising have resulted in millions being on psychiatric drugs they don’t need. One patient you describe has legitimate mourning and grief work to do after his wife leaves him for his own cousin. But his grief is pathologized into “bipolar disorder” by the system, including his own mother.

 Sinaikin: By the time I saw this patient, he was on Wellbutrin and another antidepressant, the mood stabilizers Eskaltih and Keppra, the antipyschotic Abilify, the tranquilizer Klonopin and Adderall for ADD. Calling grief a psychiatric disorder deflates and dishonors the spiritual dimension of loss and grief and the sadness which is a marker of the lost love. By the time this patient came under my care (three years after the loss of his wife) his “case” had become such a jumbled, incomprehensible and irrational mess of overdiagnosis and overmedication that the only word I can use to describe it is CRIMINAL.

Rosenberg: Can you explain the popularity of such drug cocktails? The drugs haven’t been tested together so the patient is a guinea pig. And their total cost can exceed $1000 per month, often shuttled onto taxpayers because the people are considered disabled under federal entitlement programs.

Sinaikin: Psychiatry mimics science but is not a real science. The symptoms it treats are subjective and have not been demonstrated and cannot be demonstrated at the cellular level. That gives psychiatrists free reign to just experiment and symptom chase, often insanely chasing the side effects and negative interactions of the current drug regimen with more and more drugs. Polypharmacy is also a way psychiatrists can distinguish themselves in an increasingly competitive market. No one believes you need a specialist for one drug — any primary care physician can give you Zoloft — but for multi-drug therapy you do. If you don’t write a prescription as a psychiatrist, you won’t work these days. It is like being a pacifist and having no choice but working in a bullet factory.

Rosenberg: A lot of this trial-and error polypharmacy is buttressed by the concept of “treatment resistance” and “Prozac poop-out.”

Sinaikin: I write in the book that an antidepressant not working anymore is no different than getting used to anything that used to thrill us. We buy our dream house with two bedrooms and a garage and after a while it doesn’t make us happy anymore and we are eyeing the house with three bedrooms and a pool. Another example, of course, is falling in and out of love.

Rosenberg: You document in Psychiatryland the creation of new diseases to sell drugs including adults now diagnosed with childhood disorders like ADD and children with adult disorders like bipolar and depression.

Sinaikin: One scientific article I read about the new childhood disorders sounds like a satire. Two well-respected “thought leaders” in psychiatry were debating the underlying pathology of a three-year-old girl who ran out in traffic. The first doctor believed her dangerous behavior was indicative of an Oppositional-Defiant disorder. The other doctor argued her impulsive act represented grandiose delusions where this girl believed she was special and cars could not harm her. She was, therefore, bipolar.

Rosenberg: Another shocker in your book is how everyday drug and alcohol addicts were recast as having psychiatric conditions for money.

Sinaikin: The insurance companies told the rehabs they would no longer pay for inpatient rehab for heroin, cocaine or alcohol unless there was also another Axis 1 psychiatric disorder like bipolar disorder or major depression. I was working in a drug treatment facility when the change happened. Since addicts typically complain of anxiety and depression, a completely understandable emotional response to their toxic lifestyles, it was “no problem” to add a new label and throw a few psychiatric drugs at their now relabeled “dual diagnosis.” Of course the central tenet of recovery, taking personal responsibility, was buried by the new victim narrative of self-medicating a previously undiagnosed mental illness.

Rosenberg: Treating addiction with psychiatric drugs before or instead of seeking a higher power is antithetical to the 12 Steps of Alcoholics Anonymous.

Sinaikin: As I say throughout my book, human beings are indescribably complex. There are times when the dual-diagnosis concept is necessary and helpful but clearly not applicable to 100% of the cases of addiction as it is now applied. I believe that the 12 Step model is an ideal model of recovery. Patients can have the help whenever they are truly ready, not just when someone decides to foist it on them. Most importantly, the addicts helping other addicts are doing it to facilitate their own recovery and not for ulterior motives such as money. Amazingly, in a world gone profit crazy 12 Step recovery programs are still free. I conceptualize the 12 Steps as a distillation of the spiritual principles world’s great religions but no one is forced to believe in anything including God.

Rosenberg: Given conflicts of interest at the American Psychiatric Association, which drives psychiatric diagnoses, in the FDA drug approval process itself and the legions of doctors willing to huckster for pharma as thought leaders or Key Opinion Leaders (KOLs), do you see any hope of rescuing people from Psychiatryland?

Sinaikin: The system is unbelievably bad and even worse than it looks. But, I think a goal that could be achieved would be a repeal of direct-to-consumer advertising. Patients now come into my office asking me if they have ADD or bipolar disorder or if they can have Cymbalta. When I began practicing psychiatry, long before direct-to-consumer advertising, this would never have happened.

Psychiatryland

« Return to news items


Share

Mainstream psychiatry is failing – but there is another way

Monday, July 25th, 2011

Speak Out About Psychiatry wants to change the way mentally ill people are treated in the UK

The Guardian – July 25, 2011

I am sick of seeing friends who are seriously mentally distressed neglected and damaged by mainstream psychiatry. I am fed up hearing about people being detained, locked up and forced to take damaging medication before anyone has found out why they are distressed. I am angry about children being forced to take addictive psychoactive drugs by health professionals because no one could be bothered to work out why they are playing up. I met some others who wanted to change things and together we formed an organisation called Speak Out Against Psychiatry.

Speak Out Against Psychiatry is a group of service users, carers and advocates with direct experience of the psychiatric industry. We know that people who are mentally distressed need compassionate understanding and intense social support. We know that there have been many successful units around the world that have helped people resolve their problems with little or no medication. They have been relatively cheap and successful yet they are not being taken up in the UK. Why not?

Take Western Lapland, in Finland. There, the mental healthsystem is based on a method called Open Dialogue: lots of long conversations with family and friends. It has the best outcomes for first episode psychosis in the developed world. About 80% of participants are back at work or training within two years. Very little medication is used. These results should be the envy of the medical professional yet it is mainly ignored. Similarly, the Family Care Foundation in Gothenburg, Sweden, allows seriously disturbed people to live with rural families for a year or more. They get therapy and the family can regularly talk over how things are going. It gets people off medication, a frightening contrast with the standard treatment from the NHS.

Here, psychiatrists’ main activity is diagnosis, yet many people do not find this helpful. They find talking about their lives and their symptoms helpful. Yet talking about hearing voices or the unusual ideas expressed by people experiencing psychosis is discouraged by mainstream psychiatry.

Most people who are extremely distressed have experienced immense personal trauma. Two-thirds of people diagnosed with schizophrenia had experienced physical or sexual abuse. Most psychiatrists ignore the evidence and prefer to talk about unproven brain disorders and imbalances in neurotransmitters. So the causes of mental distress are not fed back into wider social policy.

Then there are the drugs. Attention deficit hyperactivity disorder has no scientific basis and concerns about the drug Ritalin, used to ‘treat’ it are well documented. There are other ways of helping children who are in conflict with their parents and teachers that do not use potentially addictive medication. Equally, the prescribing of major tranquillisers such as Haloperidol to elderly people in hospital and nursing homes can be dangerous yet is becoming standard practice instead of developing staff skills in dealing with people experiencing dementia. Meanwhile, anti-depressants may be no more effective than a placebo. The serotonin hypothesis of depressionis rubbish. It is a marketing ploy by drug companies. Anti-depressants are potentially addictive and sometimes dangerous, yet one in three women take them some time in their lives. On top of this, electroconvulsive therapy is still used yet there has been ample research showing its dangers and it is just about useless.

Speak Out Against Psychiatry is inviting people to come along at 4pm on Wednesday 27 July, outside the Royal College of Psychiatrists, Belgrave Square, London, to tell us about their experiences of the damaging treatment they have received. We want to hear your stories and we want the Royal College to hear them too.

After the Speak Out we are going to Hyde Park for a picnic and to discuss our next move. I repeat, all the evidence shows that mainstream psychiatry and psychiatric medication is a waste of public money. There are better ways of helping people who are mentally distressed and we need to start using them.

http://www.guardian.co.uk/society/mental-health

« Return to news items


Share

The Voices Inside Their Heads – Gail Hornstein’s Approach To Understanding Madness

Wednesday, July 20th, 2011
Note from CCHR:  This is a very interesting article, and reminds us of the movie A Beautiful Mind and the great disservice it did to Nobel prize winner John Nash, by completely altering the most remarkable element that led to his recovery— the fact he refused to continue taking psychiatric drugs, thereby changing the entire success of what Nash was able to accomplish—a drug free recovery. The film portrays Nash as taking “newer medications” at the time of winning his Nobel Prize, (which was false) thereby directly implying it was psychiatric drugs that cured him.  Nash, himself, says this is pure fiction; he hadn’t take psychiatric drugs for 24 years and stated that he willed his own recovery.   Why invent a fictitious pharma-friendly ending when the truth was so much more inspiring? The fact that the screenwriter’s mother was a psychiatrist may have had something to do with the film’s distortion, Nash said. The point is that psychiatry has long refused to admit psychiatric disorders are not medical conditions, and have vehemently suppressed workable non-drug treatments to overcome mental difficulties, even of the severity experienced by John Nash.  In the 1970′s, psychiatrist Loren Mosher, Chief of Schizophrenic Research for the National Institute of Mental Health, (who openly stated the diagnoses of schizophrenia had no medical merit), established a drug-free program — Soteria House — for patients diagnosed schizophrenic, “The idea was that schizophrenia can often be overcome with the help of meaningful relationships, rather than with drugs, and such treatment would eventually lead to unquestionable healthier lives,” Mosher said. Between 85 percent and 90 percent of the acute and long-term clients were able to return to the community without use of conventional hospital treatment.

But like “A Beautiful Mind,” this amazing accomplishment was buried and discredited. According to Mosher, “By 1980, I was removed from my post altogether. All of this occurred because of my strong stand against the overuse of medication and disregard for drug-free, psychological interventions to treat psychological disorders.”

There is no doubt that people suffer from a wide range of emotional, behavioral and mental difficulties.  But psychiatric diagnoses (disorders) are not medical conditions, evidenced by the fact there is not one proven medical test for any psychiatric disorder, including “schizophrenia.”  Falsely “medicalizing”  these problems benefits only two groups—the pharmaceutical industry and the psychiatric industry—not those seeking real help.  For more information: http://www.cchrint.org/psychiatric-disorders/

The Sun – July 19, 2011
by Tracy Frisch

The complete text of this selection is available in our print edition.

TRACY FRISCH lives in Washington County, New York, where she is a freelance journalist, homesteader, and grassroots organizer leading a “zero-waste” campaign. She derives much of her bodily and spiritual sustenance from her almost-year-round vegetable garden.

As a teenager Gail Hornstein developed a fascination with first-person accounts of mental illness, and in the decades since, she has collected more than seven hundred patient memoirs, autobiographies, and witness testimonies. She likens them to survivor accounts or slave narratives, with patients struggling against the psychiatric system to make their voices heard.

According to the National Institute of Mental Health, approximately one in four Americans suffers from a diagnosable mental disorder. Our society has gone further than any other in classifying unwanted behaviors and emotions as diseases demanding medical — and often pharmaceutical — treatment.

Hornstein, now a Mount Holyoke College professor of psychology, questions whether this labeling benefits those being labeled. She also rejects the idea that psychiatric patients, however severe their symptoms, have a physical disease. Even schizophrenia and other types of psychosis, Hornstein suggests, can result from trauma, abuse, and oppression. She offers a popular course for psychology majors in which they read only books by patients, and she urges a more open-minded inquiry into what causes mental illness and how people get better.

Frisch: You express enormous empathy for those labeled “mentally ill,” yet you avoid romanticizing their lives. How do you walk this fine line?

Hornstein: I try to understand people as they understand themselves. If you ask them what their experience is or read their own accounts, you’ll find they can be articulate and psychologically sophisticated. Even people who lack formal education can offer highly nuanced descriptions of their emotional lives. I’ve adopted a phrase from my uk colleagues: “experts of their own experience.” This view helps me avoid either romanticizing their experience — seeing it in a more positive way than they do — or seeing it only as a tragedy with no redemptive qualities.

Emotional distress is highly individualized, and we shouldn’t come to any general conclusions about it. There are people who feel they’ve learned something profound from the experience of hearing voices, but there are plenty of others who are frightened and just want the voices to go away. One woman said to me, “If I could wake up tomorrow and not hear any voices, I would open up a bottle of champagne.” Yet she’d discovered the strength to get through it.

Frisch: Why do you feel so strongly about avoiding the phrase “mental illness”?

Hornstein: The term “mental illness” is heavily charged, politicized, and ambiguous. I prefer to talk about “anomalous experiences,” “extreme emotions,” and “emotional distress.” The main reason I don’t use medical language is that people who are suffering often don’t find it very helpful. No one experiences “schizophrenia” — that’s just a technical name for a lot of complicated feelings.

People who have been taught that “mental illnesses are brain diseases” see psychiatric patients as dangerous and unlikely to recover. And those in crisis are often understandably reluctant to consult mental-health professionals, because the stigma of mental illness is so severe: it’s possible to lose your job, your home, and your family as a consequence of being diagnosed with a mental illness. In cultures that take a social view of emotional distress, by contrast, people more readily seek help because they aren’t as likely to be ostracized and are assumed to be capable of full recovery.

The World Health Organization did an international study comparing outcomes for patients diagnosed with schizophrenia in “developed” countries — including the U.S., the United Kingdom, Denmark, and others — and in “developing” countries such as Colombia, Nigeria, and India. To their astonishment, they found that outcomes were much better in the developing countries. As often happens when a study produces unexpected results, the findings weren’t believed at first. So the study was repeated a few years later with a more stringent definition of what constituted improvement for the patients. The results were the same.

Two hypotheses have been put forward to explain these findings. One is that developing countries don’t use medications over the long term because they can’t afford it. Without long-term medication, patients don’t become chronically disabled. The other hypothesis is that people in developing countries are more likely to be cared for at home and be a part of their community, rather than being isolated or sent away to a hospital, and this helps them recover.

Frisch: How does what is commonly called “mental illness” differ from physical disease?

Hornstein: In psychiatry mental illness is a metaphor imposed on people’s behavior. There aren’t any physical methods of diagnosing a mental illness: There’s no blood test. There’s no mri. So-called mental illnesses are diagnosed on the basis of behavior. The “chemical-imbalance” theory was invented by the marketing departments of drug companies to try to convince doctors to prescribe their products. Some doctors say depression is just like diabetes: you have an imbalance of a neurotransmitter, the way a diabetic might need more or less insulin, and this drug will restore your balance. But with diabetes it’s possible to measure the amount of sugar and insulin in your blood. We know what a balanced level is. No doctor who has given anyone an antidepressant has ever measured the level of a neurotransmitter in the patient’s body. There is no independent means by which to tell if someone has a “chemical imbalance.”

Frisch: Do any mental illnesses have a known physiological basis?

Hornstein: The initial symptoms of Huntington’s disease resemble the symptoms of mental illness. When folk singer Woody Guthrie first manifested Huntington’s disease, he was sent to a psychiatric hospital. Similarly people in the early stages of brain cancer may behave in anomalous ways. If you don’t know they have cancer, you might think they’re having a psychiatric breakdown. But once they get a cat scan, you can see the brain tumor. You can’t see schizophrenia.

Frisch: I have always taken it for granted that only mystics or crazy people hear voices, but you suggest that it’s more common than we think.

Hornstein: Many people who hear voices never attract the attention of the psychiatric system. Estimates are that 4 percent of the uk population hears voices — approximately the same percent that has asthma. In Western society we most often associate hearing voices with illness. If we lived in a part of the world that was given to greater religiosity, unusual psychological experiences might be labeled as divine gifts. All the major religions of the world include figures who heard voices or had other anomalous psychological experiences. If the pastor in an Evangelical Christian church tells the congregation, “God spoke to me last night,” no one in that church thinks he has lost his mind.

Whether a phenomenon is considered “abnormal” or not depends on the circumstances, the person’s suffering, the reactions of others, and many more factors. One of the main goals of my book Agnes’s Jacket is to give readers the opportunity to learn about people who have unusual experiences and to encourage them to tolerate a wider range of behavior in themselves and others.

Read the rest of the article here: http://www.thesunmagazine.org/issues/427/the_voices_inside_their_heads

« Return to news items


Share

Antidepressant Nation

Thursday, July 14th, 2011

Truthdig – July 14, 2011

10 percent of Americans over age six now take antidepressants

A serious conversation is under way in the United States on the subject of psychiatric drugs. The debate consists of three fundamental issues: first, whether antidepressants actually treat depression; second, the vast, growing body of evidence that psychotropic medications alter the brain permanently; and third, the pharmaceutical industry’s continuing, decades-old corruption of American psychiatrists, many of whom have been made by drug companies’ shenanigans into little more than handsomely paid industry shills.

A careful questioning of these issues written by the spectacularly decorated Harvard Medical School lecturer Dr. Marcia Angell appeared as a two-part essay published earlier this summer in The New York Review of Books. In addition to holding a medical degree from Boston University School of Medicine and undergraduate diplomas in both chemistry and mathematics, Angell is a Fulbright Scholar, a board-certified pathologist, author of two books, a member of numerous professional health care associations and a retired 20-year staffer at the New England Journal of Medicine, which she ultimately left as editor-in-chief.

The recent publication of three books, each of which takes up one of the issues raised above, provided the occasion for Angell’s essay. In it, she argues convincingly that antidepressants are not known to do what drug companies and many psychiatrists say they do. It is this claim that drew the attention of practicing psychiatrist and Brown University professor Dr. Peter D. Kramer, who in a New York Times commentary published last Sunday questioned some but not all of what Dr. Angell wrote.

Both articles deserve to be read, but there is a crucial difference between them. While Kramer points to much data that must be taken seriously, his wandering defense of the utility of antidepressants does not undo the diligent, methodical inquiry one would expect from someone with Angell’s credentials—and which she delivers. Otherwise, he too is a critic of Big Pharma’s shady dealings. Kramer nods with genuine concern toward the dangers associated with the prolonged use of psychotropics and, in his conclusion, expresses support for treatment via effective alternatives. Both professionals agree that serious research needs to be done to understand exactly what these drugs are doing. —ARK

Marcia Angell in The New York Review of Books:

Nowadays treatment by medical doctors nearly always means psychoactive drugs, that is, drugs that affect the mental state. In fact, most psychiatrists treat only with drugs, and refer patients to psychologists or social workers if they believe psychotherapy is also warranted. The shift from “talk therapy” to drugs as the dominant mode of treatment coincides with the emergence over the past four decades of the theory that mental illness is caused primarily by chemical imbalances in the brain that can be corrected by specific drugs. That theory became broadly accepted, by the media and the public as well as by the medical profession, after Prozac came to market in 1987 and was intensively promoted as a corrective for a deficiency of serotonin in the brain. The number of people treated for depression tripled in the following ten years, and about 10 percent of Americans over age six now take antidepressants. The increased use of drugs to treat psychosis is even more dramatic. The new generation of antipsychotics, such as Risperdal, Zyprexa, and Seroquel, has replaced cholesterol-lowering agents as the top-selling class of drugs in the US.

Read Part 1: The Epidemic of Mental Illness: Why?

Read Part 2: The Illusions of Psychiatry

« Return to news items


Share

Harvard Medical School Professor Among Five Psychiatrists Accused of Ghostwriting

Wednesday, July 13th, 2011

The Harvard Crimson – July 12, 2011

—Staff writer Naveen N. Srivatsa

Photo: Keri D Mabry

A complaint filed with the federal Office of Research Integrity alleged that a group of psychiatrists, including an associate professor at the Harvard Medical School, signed their names to an academic paper written by a communications firm hired by a major pharmaceutical company.

Gary Sachs, a researcher affiliated with Massachusetts General Hospital, is one of five doctors identified in the formal accusation filed July 8 by University of Pennsylvania professor Jay D. Amsterdam.

The psychiatrists allowed the medical communications company Scientific Therapeutics Information, hired by SmithKline Beecham, to draft a paper using their names, according to the complaint. The paper, according to Amsterdam, suggested that the antidepressant Paxil can help treat some cases of bipolar disorder.

SmithKline Beecham, which has since merged into the pharmaceutical company GlaxoSmithKline, manufactured Paxil.

The practice known as ghostwriting is widely condemned by scientific journals. The World Association of Medical Editors calls ghostwriting “dishonest and unacceptable.”

The complaint includes messages sent between those affiliated with the study, as well as their supervisors. The attached messages include professors saying that Scientific Therapeutics Information and SmithKline Beecham selected the first author of the paper and failed to provide the paper to all investigators before submission.

But the messages also seem to portray a feud between Amsterdam and University of Pennsylvania Associate Professor Laszlo Gyulai, one of the accused researchers. In one message, Amsterdam accuses him of stealing his research.

“As per your investigation there is little doubt that these data were misappropriated from me and used and published without my knowledge and without regard to the significant contribution that I made to this study,” Amsterdam wrote in an email to Gyulai’s supervisor.

The paper was published in June 2001, and the research was funded by grants from GlaxoSmithKline and the National Institute of Mental Health.

In an interview Wednesday morning, Sachs, an associate clinical professor of psychiatry at Massachusetts General Hospital, said that while the relationship between Amsterdam and Gyulai was antagonistic, the accusations of research misconduct should be investigated.

“There might be unhappiness between two faculty memebers, and they might escalate this. But the question is whether there is any basis to this assertion, and this is a very serious assertion,” he said. “So apart from whatever motivations there may be, they did raise assertions, and those assertions deserve to be investigated.”

Sachs said that he was involved in designing the study and that he saw the paper before it was submitted to the journal.

While he said he did not interact with anyone from Scientific Therapeutics International, he did come in contact with employees of the pharamceutical company.

“The idea that bipolar depression was important to study has been an essential part of my career. Encouraging studies in this field is obviously, as an academic, something I’d want to do,” he said. “I was very pleased that they were willing to put their drug to the test. I give them credit of actually having the trial for the drug. Interacting with them in the course of the design and execution of the study, that’d all be standard stuff to do.”

In a statement, GlaxoSmithKline said that employees were involved in the draft’s development and that the company financially supported the study. It said that the primary authors of a paper have final approval of the draft and that when its employees provide “substantive assistance” to a paper, it is disclosed.

“This article was written more than 10 years ago and we do not have details about the development of the manuscript,” a spokesperson said in the statement. “GSK is committed to complete transparency regarding clinical and case studies.”

A spokesperson for the hospital said that it is looking into the complaint.

“Massachusetts General Hospital takes allegations of research misconduct very seriously and will handle the matter in compliance with our policy to determine if there’s any validity to the complaint,” spokesperson Kristen Stanton said in an email.

Sachs said that since the filing of the complaint, he has discussed the matter with a hospital representative.

http://www.thecrimson.com/article/2011/7/12/complaint-amsterdam-sachs-glaxosmithkline/

« Return to news items


Share